Abstract 1612P
Background
Alterations (alt) in non-BRCA homologous recombination repair (HRR) genes represent a heterogeneous group that may impact the outcome of mCRPC patients (pts) but the clinical significance of each individual gene is poorly understood. We investigated the impact of individual non-BRCA HRR alt on the outcome of mCRPC pts treated on 1L with an androgen receptor pathway inhibitor (ARPI) or a taxane.
Methods
Eligible pts included in the CAPTURE study from PROREPAIR-B (NCT03075735), PROSENZA (NCT02922218), PROSTAC (NCT02362620), and PROSABI (NCT02787837) studies underwent paired somatic/germline DNA analyses using a custom NGS panel that included ATM, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, FANCA, HDAC2, PALB2, RAD51B, and RAD54L. Pts were classified as non-BRCA HRR (ATM, FANCA, CDK12, other genes) if pathogenic (likely) alt in ≥1 allele & no concomitant BRCA alt present. rPFS and OS were reported for BRCA, non-BRCA HRR and non-HRR subgroups; association with outcome was assessed using multivariable Cox-regression models including baseline variables with known prognostic value. Hazard ratios (HR) with 95% confidence intervals (CIs) and p values are presented.
Results
Of 729 pts, 223 (30.6%) had alt in HRR genes, including 96 (13.2%) BRCA, 52 (7.3%) ATM, 26 (3.2%) FANCA, 14 (2%) CDK12 and 34 (4.8%) pts with other non-BRCA HRR alt. 1 pt with co-occurring FANCA + CDK12 mutation was excluded. After adjusting for baseline covariates, ATM alt were associated with better OS compared with BRCA alt. Pts with FANCA alt showed no difference when compared to pts with BRCA alt. Both pts with FANCA and CDK12 alt had a significantly worse OS than those without HRR alt (Table). CIs are relatively wide due to small number of pts. Table: 1612P
Comparison vs BRCA | Comparison vs non-HRR | |||
Overall survival | rPFS | Overall survival | rPFS | |
FANCA | HR 0.97 (0.58-1.62); p=0.914 | HR 1.08 (0.64-1.83); p=0.777 | HR 1.89 (1.23-2.89); p=0.003 | HR 1.92 (1.23-2.99); p=0.004 |
ATM | HR 0.65 (0.43-0.97); p=0.035 | HR 0.76 (0.50-1.15); p=0.194 | HR 1.25 (0.91-1.71); p=0.170 | HR 1.37 (0.98-1.93); p=0.067 |
CDK12 | HR 1.38 (0.68-2.77); p=0.373 | HR 1.33 (0.60-2.91); p=0.480 | HR 2.05 (1.15-3.64); p=0.015 | HR 1.54 (0.83-2.86); p=0.167 |
Other | HR 0.66 (0.42-1.03); p=0.069 | HR 0.81 (0.50-1.31); p=0.386 | HR 1.33 (0.91-1.93); p=0.139 | HR 1.42 (0.97-2.08); p=0.069 |
Conclusions
FANCA, ATM and CDK12 alt are associated with different outcomes. The marked heterogeneity in prognostic significance may not justify pooling non-BRCA HRR alt as a single entity. Further studies are needed to elucidate the clinical significance of each alt independently.
Clinical trial identification
PROREPAIR-B (NCT03075735), PROSENZA (NCT02922218), PROSTAC (NCT02362620), PROSABI (NCT02787837).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Janssen.
Disclosure
D. Lorente: Financial Interests, Personal, Invited Speaker: Janssen, Astellas, Bayer, Sanofi, Bristol Myers Squibb, AstraZeneca, MSD; Financial Interests, Personal, Advisory Board: Janssen, Sanofi, Pfizer, AstraZeneca; Financial Interests, Personal, Other, Travel: Bayer, Pfizer. B. Herrera Imbroda: Financial Interests, Personal, Advisory Board: AstraZeneca, Janssen, Astellas, Bayer; Financial Interests, Personal, Invited Speaker: Ipsen. N. Romero Laorden: Financial Interests, Personal, Advisory Role: AstraZeneca, Clovis Oncology, GSK, Janssen, MSD; Financial Interests, Institutional, Research Funding: Janssen-Cilag, MSD, Pfizer. M.J. Mendez Vidal: Financial Interests, Personal, Advisory Board: BMS, MSD, Novartis, Ipsen, Astellas, Pfizer, Merck, Sanofi, Eisai, Bayer; Financial Interests, Personal, Invited Speaker: BMS, Ipsen, Roche, Astellas, Merck, Bayer; Non-Financial Interests, Other, Travel expenses: Ipsen, BMS. C. Capone, A.M. Vanden Broecke, M. Trevisan, S. Van Sanden, A. Jürgens: Financial Interests, Personal, Full or part-time Employment: Janssen. E. Gonzalez Billalabeitia: Financial Interests, Personal, Invited Speaker: Astellas, Janssen, Bayer; Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer; Financial Interests, Personal, Other, Travel Grant: Pfizer, Janssen; Financial Interests, Institutional, Coordinating PI, IIS Phase 2 Pembrolizumab in combination with Carboplatin and Cabazitaxel in AVPC: MSD; Financial Interests, Institutional, Research Grant, Translational research project in PTEN defective prostate cancer: AstraZeneca; Financial Interests, Institutional, Research Grant, Translational research grant for biomarkers associated with a clinical trial.: Janssen. D. Olmos: Financial Interests, Personal, Advisory Board: AstraZeneca, Bayer, Clovis Oncology, Daiichi Sankyo, Janssen, MSD Oncology; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Bayer, Janssen, Pfizer, MSD; Financial Interests, Institutional, Research Funding: AstraZeneca, Bayer, Genentech/Roche, Janssen, MSD Oncology, Pfizer. E. Castro: Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Janssen, MSD, Bayer, Pfizer, Daiichi Sankyo, Lilly, Medscape, Novartis; Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, Clovis, Pfizer, Medscaoe; Financial Interests, Personal, Writing Engagement: Pfizer; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Institutional, Research Grant: Janssen, Bayer, Pfizer; Financial Interests, Institutional, Local PI: Janssen, Pfizer, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10